Publication
Clostridium Butyricum and butyrate enhance PD-1 inhibitor therapy in non-small cell lung cancer by regulating the HDAC1/ID2/IL-12R pathway.
Zhuo Chen, Meng-Lei Wang, Zhuo-Wen Zhang, Peng-Cheng Zhang, Qing-Fang Yang, Yu-Jing Weng, Jia-Long Shen, Wenxian Wang, Lan Shao
- Source
- PubMed
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260912-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: PD-1 blockade has become an important immunotherapeutic strategy, its clinical efficacy in non-small cell lung cancer (NSCLC) remains suboptimal. This study explores the effect and mechanism of sodium butyrate (NaB) and Clostridium butyricum (C. butyricum) combined with PD-1 inhibitors…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Lung Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available